PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35247917-0	2022	Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells.	BAY-876	100-107	integrator complex subunit 6	Homo sapiens	40-45
35247917-0	2022	Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells.	BAY-876	100-107	solute carrier family 2 member 1	Homo sapiens	84-89
35247917-6	2022	DBI-1 and the GLUT1 inhibitor, BAY-876, synergistically inhibit CRC cell growth in vitro and in vivo.	BAY-876	31-38	solute carrier family 2 member 1	Homo sapiens	14-19
30861255-9	2019	Similarly, BAY-876, a GLUT1 inhibitor, enhanced cisplatin-mediated inhibition of ESCC cell proliferation.	BAY-876	11-18	solute carrier family 2 member 1	Homo sapiens	22-27
35014047-4	2022	The stimulatory effects of insulin upon cell proliferation and 3 H-DG uptake were hampered by rapamycin, LY294001 and BAY-876, in both cell lines.	BAY-876	118-125	insulin	Homo sapiens	27-34
32826891-4	2020	We report that genetic or pharmacological inhibition of GLUT1 with BAY-876 impairs the growth of a subset of TNBC cells displaying high glycolytic and lower oxidative phosphorylation (OXPHOS) rates.	BAY-876	67-74	solute carrier family 2 member 1	Homo sapiens	56-61
30602670-0	2018	Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876.	BAY-876	101-108	solute carrier family 2 member 1	Homo sapiens	25-46
30602670-3	2018	Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer.	BAY-876	10-17	solute carrier family 2 member 1	Homo sapiens	89-93
30602670-3	2018	Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer.	BAY-876	10-17	solute carrier family 2 member 1	Homo sapiens	66-87
30602670-3	2018	Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer.	BAY-876	10-17	solute carrier family 2 member 1	Homo sapiens	89-94
34954641-8	2022	Taken together, this study elucidated the pharmacological mechanism of plumbagin by targeting TrxR1 and revealed the synergy effect of plumbagin and BAY-876, which may be helpful for applying naphthoquinone compounds to chemotherapy, particularly for treating KEAP1-mutant NSCLC cells.	BAY-876	149-156	kelch like ECH associated protein 1	Homo sapiens	260-265
30602670-10	2018	BAY-876 is a potent blocker of GLUT1 activity, glycolytic metabolism and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.	BAY-876	0-7	solute carrier family 2 member 1	Homo sapiens	31-36
29857184-2	2018	In this study, we confirm that quercetin is a competitive inhibitor of GLUT1 and also demonstrate that newly synthesized compounds, WZB-117 and BAY-876 are robust inhibitors of GLUT1 in L929 cells.	BAY-876	144-151	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	177-182
27552707-0	2016	Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.	BAY-876	78-85	solute carrier family 2 member 1	Homo sapiens	62-67
34906161-16	2021	We accordingly investigated the efficacy of GLUT1 inhibitor (BAY-876) in BLCA and determined its IC50 values across cell lines.	BAY-876	61-68	solute carrier family 2 member 1	Homo sapiens	44-49
34973363-7	2022	NADPH bankrupt caused by glucose starvation or glucose limitation (inhibiting glucose transporter 1 by BAY-876) could efficiently overcome the resistance of KEAP1-mutant NSCLC cells to shikonin.	BAY-876	103-110	kelch like ECH associated protein 1	Homo sapiens	157-162
34906161-17	2021	Tumor xenograft models further validated that BAY-876 could effectively suppress the in vivo growth of TRIM38low/- BLCA.	BAY-876	46-53	tripartite motif containing 38	Homo sapiens	103-109
34461288-9	2021	Interestingly, we administrated two GLUT inhibitors (BAY-876 and Fasentin) in rats injected glucose and found that these two inhibitors could reverse the defects of IDD by decreasing apoptosis.	BAY-876	53-60	glutaminase	Rattus norvegicus	36-40
34869036-5	2021	The clinical role of BAY-876 was confirmed by the increased expression of GLUT1, which was associated with the worse prognosis among advanced HCC patients.	BAY-876	21-28	solute carrier family 2 member 1	Homo sapiens	74-79